Comparative Pharmacology
Head-to-head clinical analysis: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE versus PROCHLORPERAZINE MALEATE.
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxylamine succinate is a histamine H1 receptor antagonist with sedative properties; pyridoxine hydrochloride is a vitamin B6 derivative that acts as a coenzyme in amino acid, carbohydrate, and lipid metabolism. The combination is believed to reduce nausea and vomiting through central anticholinergic effects and pyridoxine supplementation.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
1 tablet (doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg) orally twice daily (morning and evening), increased to three times daily if needed (one tablet in the morning, one in the afternoon, and two at bedtime). Maximum: 4 tablets per day.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Doxylamine: terminal half-life 10-12 hours; steady state reached in 3-4 days. Pyridoxine: half-life 15-20 days for body stores, but plasma half-life of pyridoxal phosphate ~15-30 minutes.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Doxylamine: ~60% renal as unchanged drug and metabolites; Pyridoxine: primarily renal as 4-pyridoxic acid and other metabolites. Up to 70% of pyridoxine metabolites excreted in urine within 24 hours.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category C
Category A/B
Antiemetic
Typical Antipsychotic / Antiemetic